36-Year-Old with Nail Deformities

  • Michael P. Lee
  • Kevin K. Wu
  • Jashin J. Wu
Part of the Clinical Cases in Dermatology book series (CLIDADE)


Nail psoriasis is a common manifestation in patients with psoriasis and is characterized by pitting, onycholysis, subungual hyperkeratosis, and nail discoloration. The Nail Psoriasis Severity Index (NAPSI) can be utilized to assess the severity of disease as well as the response to treatment. Treatment largely involves topical medications as extent of the disease must be taken into consideration if using biologics due to increased risk of adverse effects. This was a case of a 36-year-old postpartum female with nail psoriasis treated with fluocinolone topical ointment and instructed to add calcipotriene after finishing nursing.


Nail psoriasis NAPSI 


  1. 1.
    Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg. 2003;7(4):317–21. Scholar
  2. 2.
    Tan ES, Chong WS, Tey HL. Nail psoriasis: a review. Am J Clin Dermatol. 2012;13(6):375–88. Scholar
  3. 3.
    Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123–8. Scholar
  4. 4.
    Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1–27. Scholar
  5. 5.
    Armesto S, Esteve A, Coto-Segura P, Drake M, Galache C, Martinez-Borra J, Santos-Juanes J. [Nail psoriasis in individuals with psoriasis vulgaris: a study of 661 patients]. Actas Dermosifiliogr. 2011;102(5):365–72. Scholar
  6. 6.
    Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206–12.CrossRefGoogle Scholar
  7. 7.
    Wolf R, Tur E, Brenner S. Corticosteroid-induced ‘disappearing digit’. J Am Acad Dermatol. 1990;23(4. Pt 1):755–6.CrossRefGoogle Scholar
  8. 8.
    Rigopoulos D, Gregoriou S, Daniel Iii CR, Belyayeva H, Larios G, Verra P, Stamou C, Kontochristopoulos G, Avgerinou G, Katsambas A. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009;218(4):338–41. Scholar
  9. 9.
    Tosti A, Piraccini BM, Cameli N, Kokely F, Plozzer C, Cannata GE, Benelli C. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol. 1998;139(4):655–9.CrossRefGoogle Scholar
  10. 10.
    Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis. 2001;68(5):355–8.PubMedGoogle Scholar
  11. 11.
    De Simone C, Maiorino A, Tassone F, D’Agostino M, Caldarola G. Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study. J Eur Acad Dermatol Venereol. 2013;27(8):1003–6. Scholar
  12. 12.
    Crowley JJ, Weinberg JM, Wu JJ, Robertson AD, Van Voorhees AS, National Psoriasis F. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol. 2015;151(1):87–94. Scholar
  13. 13.
    Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y, Kerkmann U, Ghislain PD, Poulin Y, investigators P. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. 2014;170(2):398–407. Scholar
  14. 14.
    van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, Morita A, Goldblum O, Zhang L, Erickson J, Ball S, Rich P. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31(3):477–82. Scholar
  15. 15.
    Nguyen CM, Leon A, Danesh M, Beroukhim K, Wu JJ, Koo J. Improvement of nail and scalp psoriasis using apremilast in patients with chronic psoriasis: phase 2b and 3, 52-week randomized, placebo-controlled trial results. J Drugs Dermatol. 2016;15(3):272–6.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Michael P. Lee
    • 1
  • Kevin K. Wu
    • 2
  • Jashin J. Wu
    • 3
  1. 1.Eastern Virginia Medical SchoolNorfolkUSA
  2. 2.Frank H. Netter MD School of Medicine at Quinnipiac UniversityNorth HavenUSA
  3. 3.Founder and CEODermatology Research and Education FoundationIrvineUSA

Personalised recommendations